NCT00712400View on ClinicalTrials.gov

Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

January 31, 2010

Conditions
Ocular PhysiologyIntraocular PressureRegional Blood Flow
Interventions
DRUG

Latanoprost 0.005%, Xalatan®

Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days

DRUG

Placebo

Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days

Trial Locations (1)

1090

Department of Clinical Pharmacology, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00712400 - Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects | Biotech Hunter | Biotech Hunter